- Home
- IMMX vs SER Comparison
IMMX vs SER Comparison
Compare IMMX & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- SER
- Stock Information
- Founded
- IMMX 2014
- SER 2017
- Country
- IMMX United States
- SER United States
- Employees
- IMMX N/A
- SER N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- SER Health Care
- Exchange
- IMMX Nasdaq
- SER Nasdaq
- Market Cap
- IMMX 61.1M
- SER 56.5M
- IPO Year
- IMMX 2021
- SER 2018
- Fundamental
- Price
- IMMX $2.74
- SER $5.71
- Analyst Decision
- IMMX Strong Buy
- SER Strong Buy
- Analyst Count
- IMMX 1
- SER 2
- Target Price
- IMMX $7.00
- SER $13.00
- AVG Volume (30 Days)
- IMMX 209.7K
- SER 31.0K
- Earning Date
- IMMX 08-11-2025
- SER 08-08-2025
- Dividend Yield
- IMMX N/A
- SER N/A
- EPS Growth
- IMMX N/A
- SER N/A
- EPS
- IMMX N/A
- SER N/A
- Revenue
- IMMX N/A
- SER $51,000.00
- Revenue This Year
- IMMX N/A
- SER N/A
- Revenue Next Year
- IMMX N/A
- SER N/A
- P/E Ratio
- IMMX N/A
- SER N/A
- Revenue Growth
- IMMX N/A
- SER N/A
- 52 Week Low
- IMMX $1.26
- SER $3.81
- 52 Week High
- IMMX $3.20
- SER $11.57
- Technical
- Relative Strength Index (RSI)
- IMMX 52.53
- SER 57.60
- Support Level
- IMMX $2.74
- SER $5.11
- Resistance Level
- IMMX $3.20
- SER $5.67
- Average True Range (ATR)
- IMMX 0.23
- SER 0.38
- MACD
- IMMX -0.03
- SER 0.05
- Stochastic Oscillator
- IMMX 15.25
- SER 66.22
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.